Zenocutuzumab · Bizengri
Multispecific antibody
Also known as MCLA-128
Evidence outlook
Approved: Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Cholangiocarcinoma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02912949 NCT02912949 · Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion Registry: NCT02912949 | 2 | Objective overall response rate (ORR) as per local investigator's assessment (36 months); Duration of response per RECIST v1.1 as per local Investigator's assessment. (36 Months) 2026-12-31 | In progress: results expected 31 Dec 2026 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (3)
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Cholangiocarcinoma: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Zenocutuzumab (Bizengri): this drug | Approved | Multispecific antibody | HER2; HER3 (blocks NRG1 binding to HER3) | not yet graded | No reviewed efficacy summary in this indication | |
| Futibatinib (Lytgobi) | Approved | Small molecule | FGFR (FGFR1/2/3/4) | Weak signal | No reviewed efficacy summary in this indication | |
| Lirafugratinib (Lyrfigtu) | Approved | Small molecule | FGFR2 | not yet graded | No reviewed efficacy summary in this indication | |
| Pemigatinib (Pemazyre) | Approved | Small molecule | FGFR1/2/3 | Weak signal | No reviewed efficacy summary in this indication | |
| Tinengotinib | Phase 3 | Small molecule | Aurora A/B kinase (with secondary FGFR1/2/3, VEGFR1, JAK1/2, CSF1R inhibition) | Weak signal | Featured results are safety only in this race | |
| Toripalimab | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Crelosidenib | Phase 1 | Small molecule | Mutant IDH1 and IDH2 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Bizengri (Zenocutuzumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent